Skip to main content

Table 3 Control of asthma assessed by the physician using VAS, ACQ score and GINA classification

From: Severity and disease control before house dust mite immunotherapy initiation: ANTARES a French observational survey

ACQ

<1 

N = 164

1–1.5 

N = 78

≥1.5 

N = 128

p value**

Control of asthma (VAS)

 N available

164

78

128

 

 Mean ± SD

8.64 ± 1.79

7.41 ± 2.63

6.10 ± 2.67

<0.001

 Median

9.4

8.3

6.5

 

 Min, Max

1.8, 10.0

0.8, 10.0

0.6, 10.0

 

GINA classification

Controlled

N = 366

Partly controlled

N = 184

Uncontrolled

N = 38

p value**

Control of asthma (VAS)

 N available

366

184

38

 

 Mean ± SD

8.8 ± 1.8

5.8 ± 2.0

2.5 ± 2.2

<0.001

 Median

9.4

6.2

1.8

 

 Min., Max

0.0, 10.0

0.8, 9.3

0.0, 8.4

 

Treatment steps according to GINA classification

AIT

No-AIT

Total

p value**

Children (N = 279)

 N available

224

46

270

 

 Missing

7

2

9

 

 Step 1

67 (29.9 %)

13 (28.3 %)

80 (29.6 %)

0.102

 Step 2

70 (31.3 %)

15 (32.6 %)

85 (31.5 %)

 

 Step 3

73 (32.6 %)

15 (32.6 %)

88 (32.6 %)

 

 Step 4

14 (6.3 %)

1 (2.2 %)

15 (5.6 %)

 

 Step 5

0 (0.0 %)

2 (4.3 %)

2 (0.7 %)

 

 N available

224

46

270

 

Adults (N = 328)

 N available

265

53

318

 

 Missing

9

1

10

 

 Step 1

103 (38.9 %)

18 (34.0 %)

121 (38.1 %)

0.502

 Step 2

61 (23.0 %)

18 (34.0 %)

79 (24.8 %)

 

 Step 3

81 (30.6 %)

15 (28.3 %)

96 (30.2 %)

 

 Step 4

19 (7.2 %)

2 (3.8 %)

21 (6.6 %)

 

 Step 5

1 (0.4 %)

0 (0.0 %)

1 (0.3 %)

 

Total (N = 613)a

 N available

490

103

593

 

 Missing

17

3

20

 

 Step 1

170 (34.7 %)

32 (31.1 %)

202 (34.1 %)

0.066

 Step 2

132 (26.9 %)

36 (35.0 %)

168 (28.3 %)

 

 Step 3

154 (31.4 %)

30 (29.1 %)

184 (31.0 %)

 

 Step 4

33 (6.7 %)

3 (2.9 %)

36 (6.1 %)

 

 Step 5

1 (0.2 %)

2 (1.9 %)

3 (0.5 %)

 
  1. ** Kruskal–Wallis test or Fisher’s exact test
  2. aThe total population corresponding to the whole population of asthmatics (N = 613) that included patients with missing age (N = 6)